BackPDL Biopharma Overview

PDL Biopharma Accounts Payable

PDL Biopharma's accounts payable is $2.7M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$2.67M
79.82% YoYΔ $-10.58M vs prior year quarter

Peer average

Loading

PDL Biopharma Accounts Payable History

Loading

PDL Biopharma vs. peers: Accounts Payable Comparison

Loading

PDL Biopharma Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

PDL Biopharma (PDLI) FAQ

As of the most recent data (September 2020), PDLI shows a accounts payable of $2.7M. That compares with $13M in the prior-year period — down 79.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PDLI's accounts payable is now $2.7M (was $13M) — a 79.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.

Tracking PDLI's accounts payable over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.7M That compares with $13M in the prior-year period — down 79.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.7M) with ownership activity and broader fundamentals.

PDL Biopharma's accounts payable is $2.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.